Other analysts also recently issued reports about the company. Zacks Investment Research downgraded ANI Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, July 31st. Raymond James downgraded ANI Pharmaceuticals from a strong-buy rating to an outperform rating and lifted their price objective for the company from $73.00 to $82.00 in a report on Friday, May 10th. Cantor Fitzgerald restated a buy rating and issued a $89.00 price objective on shares of ANI Pharmaceuticals in a report on Thursday, May 9th. ValuEngine downgraded ANI Pharmaceuticals from a buy rating to a hold rating in a report on Thursday, August 1st. Finally, Canaccord Genuity restated a buy rating and issued a $90.00 price objective (up from $80.00) on shares of ANI Pharmaceuticals in a report on Monday, May 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $89.00.
NASDAQ:ANIP opened at $67.09 on Tuesday. ANI Pharmaceuticals has a twelve month low of $36.92 and a twelve month high of $86.96. The company has a market cap of $871.52 million, a price-to-earnings ratio of 14.55 and a beta of 2.17. The stock has a fifty day simple moving average of $80.45 and a 200-day simple moving average of $70.60. The company has a current ratio of 1.01, a quick ratio of 0.74 and a debt-to-equity ratio of 0.32.
ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.26. The business had revenue of $54.36 million during the quarter, compared to the consensus estimate of $55.20 million. ANI Pharmaceuticals had a return on equity of 29.53% and a net margin of 8.14%. The business’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period last year, the company earned $1.13 earnings per share. As a group, equities research analysts predict that ANI Pharmaceuticals will post 5.29 EPS for the current fiscal year.
In related news, Director David Nash bought 1,445 shares of the business’s stock in a transaction on Friday, May 24th. The shares were bought at an average price of $68.76 per share, for a total transaction of $99,358.20. Following the completion of the purchase, the director now directly owns 5,236 shares of the company’s stock, valued at $360,027.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Meridian Venture Partners Ii L sold 61,697 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $71.64, for a total value of $4,419,973.08. The disclosure for this sale can be found here. Insiders own 24.70% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of ANIP. Invesco Ltd. grew its stake in ANI Pharmaceuticals by 113.9% in the second quarter. Invesco Ltd. now owns 214,240 shares of the specialty pharmaceutical company’s stock valued at $17,611,000 after purchasing an additional 114,084 shares during the last quarter. Global Alpha Capital Management Ltd. purchased a new position in ANI Pharmaceuticals in the first quarter valued at about $6,808,000. Nomura Holdings Inc. grew its stake in ANI Pharmaceuticals by 34.1% in the second quarter. Nomura Holdings Inc. now owns 375,449 shares of the specialty pharmaceutical company’s stock valued at $31,071,000 after purchasing an additional 95,462 shares during the last quarter. Renaissance Technologies LLC grew its stake in ANI Pharmaceuticals by 44.6% in the second quarter. Renaissance Technologies LLC now owns 288,100 shares of the specialty pharmaceutical company’s stock valued at $23,682,000 after purchasing an additional 88,900 shares during the last quarter. Finally, Nuveen Asset Management LLC purchased a new position in ANI Pharmaceuticals in the second quarter valued at about $7,071,000. Institutional investors own 64.22% of the company’s stock.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Read More: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.